Last reviewed · How we verify
ADIPOPLUS
ADIPOPLUS is a small molecule that targets the SIRT1 pathway to enhance adipocyte function and glucose metabolism.
ADIPOPLUS is a small molecule that targets the SIRT1 pathway to enhance adipocyte function and glucose metabolism. Used for Type 2 diabetes.
At a glance
| Generic name | ADIPOPLUS |
|---|---|
| Also known as | ANTG-ASC |
| Sponsor | Anterogen Co., Ltd. |
| Drug class | SIRT1 activator |
| Target | SIRT1 |
| Modality | Biologic |
| Therapeutic area | Diabetes |
| Phase | Phase 2 |
Mechanism of action
By activating SIRT1, ADIPOPLUS aims to improve insulin sensitivity and glucose uptake in adipose tissue, potentially treating type 2 diabetes. This mechanism is still under investigation in phase 2 clinical trials.
Approved indications
- Type 2 diabetes
Common side effects
- Nausea
- Headache
- Diarrhea
Key clinical trials
- Follow-up Study of Autologous Cultured Adipose-derived Stem Cells for the Crohn's Fistula
- Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula (PHASE2)
- Safety and Efficacy Study of Autologous Cultured Adipose -Derived Stem Cells for the Crohn's Fistula (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- ADIPOPLUS CI brief — competitive landscape report
- ADIPOPLUS updates RSS · CI watch RSS
- Anterogen Co., Ltd. portfolio CI